EM1910I "Immunotherapy in Lung Cancer Treatment: A New Paradigm Still in Revision" (IM GR-101119)
To discuss changing paradigms in the treatment of advanced lung cancer with immune checkpoint blockade. Antibodies against inhibitory T cell immune check¬points have now become standard of treatment in the first- and second-line therapies for meta¬static lung cancer. We will review the role of T cell immune check points in tumor biology, a brief overview of the clinical data of immune checkpoint inhibitors, attempts to identify predictive bio¬markers, and a discussion of immune related adverse events from T cell checkpoint blockade.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Review biology of T cell immune checkpoint blockade
- Review the new immune checkpoint inhibitors and their roles in the treatment of lung can¬cers.
- Review controversies in identification of predictive biomarkers for the immune checkpoint inhibitors
- Review the immune-related adverse events from immune checkpoint blockade and their management
James Kim, M.D., Ph.D.
Assistant Professor of Internal Medicine
Division of Hematology and Oncology
- 1.00 AMA